Analyst Research

Report Title Price
Thomson Reuters Stock Report - CELL BIOTECH CO ., LIMITED. (049960-KQ)
Provider: Thomson Reuters Stock Report
$25.00
Buy
Cell Biotech Co Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
Cell Biotech Co., Ltd. (049960) - Financial Analysis Review
Provider: GlobalData
$125.00
Buy
Cell Biotech Co., Ltd. (049960) - Financial Analysis Review
Provider: GlobalData
$125.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Cell Biotech Co., Ltd. Issues FY 2012 Revenue Outlook Above Analysts' Estimates


Friday, 20 Jul 2012 05:05am EDT 

Cell Biotech Co., Ltd. announced that it expects the revenue for the fiscal year 2012 to record KRW 27 billion and operating profit, to record KRW 6.8 billion. According to I/B/E/S, analysts on average are expecting the Company to report revenue of KRW 25.50 billion for fiscal year 2012. 

Latest Key Developments in Biotechnology

Company Quote

Cell Biotech Co Ltd
(049960.KQ)
17000.0
750.0 +4.62%
24 May 2013